Title : FGF23, Hypophosphatemia, and Emerging Treatments.

Pub. Date : 2019 Aug

PMID : 31485552






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 FGF23-mediated forms of hypophosphatemia are characterized by phosphaturia and low or low-normal calcitriol concentrations, and unlike nutritional rickets, these cannot be cured with nutritional vitamin D supplementation. Vitamin D fibroblast growth factor 23 Homo sapiens
2 Historically phosphate supplementation and therapy using analogs of highly active vitamin D (eg, calcitriol, alfacalcidol, paricalcitol, eldecalcitol) have been used to manage conditions involving hypophosphatemia; however, recently a neutralizing antibody for FGF23 (burosumab) has emerged as a promising treatment agent for FGF23-mediated disorders. Vitamin D fibroblast growth factor 23 Homo sapiens
3 Historically phosphate supplementation and therapy using analogs of highly active vitamin D (eg, calcitriol, alfacalcidol, paricalcitol, eldecalcitol) have been used to manage conditions involving hypophosphatemia; however, recently a neutralizing antibody for FGF23 (burosumab) has emerged as a promising treatment agent for FGF23-mediated disorders. Vitamin D fibroblast growth factor 23 Homo sapiens